Company news
Arrivent Biopharma, Inc. (NASDAQ:AVBP) news
Arrivent Biopharma, Inc. news releases on 6ix. Latest, Oct 6, 2026: ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib…
Press releases & updates
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
October 5, 2026
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
October 6, 2026
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 10, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
March 17, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
March 4, 2026
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
December 21, 2025
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
November 9, 2025
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
September 21, 2025
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
September 8, 2025
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
August 10, 2025
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
July 20, 2025
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
June 30, 2025
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
June 30, 2025
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
June 22, 2025
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
June 19, 2025
ArriVent BioPharma Reports First Quarter 2025 Financial Results
May 11, 2025
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
April 27, 2025
ArriVent BioPharma Reports Full Year 2024 Financial Results
March 2, 2025
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 20, 2025
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
November 13, 2024
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
September 8, 2024
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
August 13, 2024
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
August 11, 2024
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
June 4, 2024
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
May 15, 2024
ArriVent BioPharma Reports First Quarter 2024 Financial Results
May 7, 2024
ArriVent Appoints Kristine Peterson to its Board of Directors
April 21, 2024
ArriVent BioPharma Reports Full Year 2023 Financial Results
March 27, 2024